since 1992, omnicell has been creating new efficiencies to improve patient care, anywhere it is delivered. omnicell is a leading supplier of comprehensive automation and business analytics software for patient-centric medication and supply management across the entire health care continuum—from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. omnicell’s automated hardware/software systems for medication dispensing include solutions from the point of entry into the hospital through the central pharmacy, nursing unit, operating room, and patient bedside. our supply management systems promote greater cost control and charge capture for payer reimbursement, and improve management and reordering of inventory. omnicell® products range from high-security, closed-cabinet systems and software to open-shelf and combination systems in the nursing unit, cath lab, and operating room. more than 3,200 customers worldwide have utilized omnice
Company profile
Ticker
OMCL
Exchange
Website
CEO
Randall Lipps
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
OMNICELL COM /CA/, OMNICELL INC /CA/, OMNICELL, Inc
SEC CIK
Corporate docs
Subsidiaries
Omnicell Pty Ltd • Omnicell (Beijing) Technology Co. Ltd • Omnicell GmbH • Omnicell SAS • Omnicell S.r.l. • Omnicell India Private Limited • Omnicell B.V. • Omnicell Limited • Hub and Spoke Innovations Limited • ateb, Inc. ...
IRS number
943166458
OMCL stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
11 Apr 24
DEF 14A
Definitive proxy
4 Apr 24
8-K
Departure of Directors or Certain Officers
29 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Omnicell Announces Fiscal Year and Fourth Quarter 2023 Results
8 Feb 24
8-K
Omnicell Elects Eileen Voynick to Board of Directors
11 Jan 24
8-K
Departure of Directors or Certain Officers
9 Nov 23
10-Q
2023 Q3
Quarterly report
3 Nov 23
8-K
Updates Fiscal Year 2023 Guidance and Announces Reduction in Force
2 Nov 23
8-K
Entry into a Material Definitive Agreement
16 Oct 23
Transcripts
OMCL
Earnings call transcript
2023 Q4
8 Feb 24
OMCL
Earnings call transcript
2023 Q3
2 Nov 23
OMCL
Earnings call transcript
2023 Q2
1 Aug 23
OMCL
Earnings call transcript
2023 Q1
2 May 23
OMCL
Earnings call transcript
2022 Q4
28 Feb 23
OMCL
Earnings call transcript
2022 Q3
2 Nov 22
OMCL
Earnings call transcript
2022 Q2
7 Aug 22
OMCL
Earnings call transcript
2022 Q1
1 May 22
OMCL
Earnings call transcript
2021 Q4
15 Feb 22
OMCL
Earnings call transcript
2021 Q3
2 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 462.70 mm | 462.70 mm | 462.70 mm | 462.70 mm | 462.70 mm | 462.70 mm |
Cash burn (monthly) | (no burn) | (no burn) | (no burn) | 3.48 mm | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | n/a | 23.97 mm | n/a | n/a |
Cash remaining | n/a | n/a | n/a | 438.73 mm | n/a | n/a |
Runway (months of cash) | n/a | n/a | n/a | 126.2 | n/a | n/a |
Institutional ownership, Q3 2023
97.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 304 |
Opened positions | 56 |
Closed positions | 54 |
Increased positions | 99 |
Reduced positions | 106 |
13F shares | Current |
---|---|
Total value | 2.00 tn |
Total shares | 44.72 mm |
Total puts | 81.40 k |
Total calls | 55.30 k |
Total put/call ratio | 1.5 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 7.86 mm | $354.06 bn |
Vanguard | 5.14 mm | $231.37 bn |
Wellington Management | 2.34 mm | $105.29 bn |
STT State Street | 1.88 mm | $84.61 bn |
Champlain Investment Partners | 1.58 mm | $71.36 bn |
Clearbridge Advisors | 1.33 mm | $60.12 bn |
BK Bank Of New York Mellon | 1.29 mm | $58.14 bn |
Credit Suisse | 1.06 mm | $47.67 bn |
Dimensional Fund Advisors | 1.05 mm | $47.10 bn |
MS Morgan Stanley | 968.85 k | $43.64 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Mar 24 | Corey J Manley | Common Stock | Payment of exercise | Dispose F | No | No | 27.69 | 83 | 2.30 k | 50,952 |
15 Mar 24 | Spears Joseph Brian | Common Stock | Payment of exercise | Dispose F | No | No | 27.69 | 56 | 1.55 k | 14,757 |
27 Feb 24 | Corey J Manley | Common Stock | Grant | Acquire A | No | No | 0 | 31,965 | 0.00 | 51,035 |
27 Feb 24 | Nchacha Etta | Common Stock | Grant | Acquire A | No | No | 0 | 37,853 | 0.00 | 76,999 |
27 Feb 24 | Randall A Lipps | Common Stock | Grant | Acquire A | No | No | 0 | 107,251 | 0.00 | 210,451 |
News
Clover Health Appoints Peter Kuipers As Chief Financial Officer, Effective As Of The Day After The Filing Of The Co's Quarterly Report On Form 10-Q For The Quarter-Ended March 31, 2024
22 Apr 24
Omnicell Announces XT Amplify, A Multi-Year Innovation Program That Is Intended To Maximize Value For Hospitals, Health Systems, And Post-Acute Care Facilities That Have Invested In Omnicell's XT Automated Dispensing System
16 Apr 24
Benchmark Maintains Buy on Omnicell, Lowers Price Target to $38
9 Feb 24
Wells Fargo Maintains Equal-Weight on Omnicell, Lowers Price Target to $26
9 Feb 24
Omnicell Expects Q1 Revenue of $232M-$242M Vs $262.37M Est, Adj EPS of ($0.10)-$0.00 Vs $0.31 Est, FY24 Revenue of $1.045B-$1.120B Vs $1.08B Est, Adj EPS of $0.90-$1.40 Vs $1.66 Est
8 Feb 24
Press releases
Clover Health Appoints Healthcare Technology Veteran Peter Kuipers as Chief Financial Officer
22 Apr 24
Omnicell Announces XT Amplify
16 Apr 24
Omnicell to Release First Quarter 2024 Financial Results on May 2, 2024
8 Apr 24
Omnicell to Present at the virtual KeyBanc Annual Life Sciences & MedTech Investor Forum
11 Mar 24
Omnicell Announces Fiscal Year and Fourth Quarter 2023 Results
8 Feb 24